Wuxi Pharma Tech Eyes Local Collaboration
This article was originally published in PharmAsia News
Leading Chinese CRO Wuxi Pharma Tech has partnered with more than 80 major pharmaceutical corporations worldwide in conducting R&D for new drugs. However, it has yet to work with local pharmaceutical enterprises in China, and expressed interest in collaborating with domestic partners. Because of the high cost of R&D outsourcing, local companies mainly produce generic drugs rather than conduct research by R&D outsourcing. Analysts believe the next five years will see China becoming one of the top medical consumers globally, and new CROs are set to change the concept of drug manufacturing in the country. (Click here for more - Chinese Language)
You may also be interested in...
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
Breakthrough solutions based on new biological entities (ADCs and mAbs) are making hope real for patients with conditions of high unmet medical need. Byondis is developing therapies that target intractable cancers and autoimmune diseases and taking precision medicine to the next level.
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.